KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,861 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,861 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $49,837.58. Following the transaction, the insider owned 55,780 shares in the company, valued at $1,493,788.40. The trade was a 3.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64.

KalVista Pharmaceuticals Price Performance

Shares of KALV stock opened at $26.81 on Wednesday. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.83 and a 1 year high of $26.85. The firm’s 50 day moving average is $21.74 and its 200-day moving average is $17.54. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.75 and a beta of -0.12. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $39.17 million for the quarter, compared to the consensus estimate of $39.03 million. Sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus upped their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. HC Wainwright lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $37.00 to $27.00 in a research report on Friday, May 1st. JonesTrading lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Needham & Company LLC lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $30.60.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $24,360,000. Jefferies Financial Group Inc. acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $3,494,000. Blue Owl Capital Holdings LP acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $1,522,000. Hennion & Walsh Asset Management Inc. raised its position in shares of KalVista Pharmaceuticals by 93.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after acquiring an additional 165,236 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ raised its holdings in KalVista Pharmaceuticals by 391.9% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock worth $2,449,000 after purchasing an additional 160,128 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.